Diagnostic Accuracy of BRAF Immunohistochemistry in Colorectal Cancer: a Meta-Analysis and Diagnostic Test Accuracy Review

[1]  J. Pyo,et al.  Concordance Rate between HER2 Immunohistochemistry and in Situ Hybridization in Gastric Carcinoma: Systematic Review and Meta-Analysis , 2016, The International journal of biological markers.

[2]  E. Vakiani,et al.  Immunohistochemical Detection of the BRAF V600E Mutant Protein in Colorectal Neoplasms , 2015, Applied immunohistochemistry & molecular morphology : AIMM.

[3]  J. Pyo,et al.  BRAF Immunohistochemistry Using Clone VE1 is Strongly Concordant with BRAFV600E Mutation Test in Papillary Thyroid Carcinoma , 2015, Endocrine Pathology.

[4]  W. Frankel,et al.  A modified Lynch syndrome screening algorithm in colon cancer: BRAF immunohistochemistry is efficacious and cost beneficial. , 2015, American journal of clinical pathology.

[5]  D. Barras,et al.  BRAF Mutation in Colorectal Cancer: An Update , 2015, Biomarkers in cancer.

[6]  A. Soltanian,et al.  A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer , 2015, Breast Cancer.

[7]  P. Waring,et al.  Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma , 2014, Pathology.

[8]  Markku Miettinen,et al.  Detection of the BRAF V600E Mutation in Colon Carcinoma: Critical Evaluation of the Imunohistochemical Approach , 2014, The American journal of surgical pathology.

[9]  S. Hong,et al.  A testing algorithm for detection of the B-type Raf kinase V600E mutation in papillary thyroid carcinoma. , 2014, Human pathology.

[10]  P. Gibbs,et al.  A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer , 2014, Targeted Oncology.

[11]  Weei‐Yuarn Huang,et al.  The Utility of BRAFV600E Mutation-specific Antibody for Colon Cancers With Microsatellite Instability , 2014, Applied immunohistochemistry & molecular morphology : AIMM.

[12]  Aung Ko Win,et al.  BRAFV600E Immunohistochemistry Facilitates Universal Screening of Colorectal Cancers for Lynch Syndrome , 2013, The American journal of surgical pathology.

[13]  A. Voigt,et al.  BRAF V600E‐specific immunohistochemistry for the exclusion of Lynch syndrome in MSI‐H colorectal cancer , 2013, International journal of cancer.

[14]  T. Grogan,et al.  Mutation‐specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas , 2013, Cancer.

[15]  J. Hornick,et al.  Immunohistochemistry using the BRAF V600E mutation‐specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma , 2013, Histopathology.

[16]  M. Bronner,et al.  BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma , 2013, Genes, chromosomes & cancer.

[17]  Ali Salajegheh,et al.  Clinicopathological relevance of BRAF mutations in human cancer , 2013, Pathology.

[18]  Hyun Joo Lee,et al.  Activation of nuclear factor-κB contributes to growth and aggressiveness of papillary thyroid carcinoma. , 2013, Pathology, research and practice.

[19]  Alexia Iasonos,et al.  BRAF Mutation is associated with early stage disease and improved outcome in patients with low‐grade serous ovarian cancer , 2013, Cancer.

[20]  A. von Deimling,et al.  Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma , 2013, The American journal of surgical pathology.

[21]  A. Spurdle,et al.  Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification , 2012, Journal of Medical Genetics.

[22]  S. Pileri,et al.  BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.

[23]  Larissa V Furtado,et al.  Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer , 2011, Genes, chromosomes & cancer.

[24]  J. O’Leary,et al.  BRAFV600E: Implications for Carcinogenesis and Molecular Therapy , 2011, Molecular Cancer Therapeutics.

[25]  S. Ariyan,et al.  Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032 , 2010, Journal of Translational Medicine.

[26]  Javier Zamora,et al.  Meta-DiSc : a software for meta-analysis of test accuracy data , 2015 .

[27]  L E Moses,et al.  Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. , 1993, Statistics in medicine.